[1] |
HAN Xiangchen, LI Xiaoguang, HU Xin.
Single-cell RNA sequencing and its application in breast cancer
[J]. China Oncology, 2021, 31(11): 1110-1114.
|
[2] |
JIANG Mengyi , LU Yanqiao , WANG Hongxia .
Research progress and clinical significance of breast cancer heterogeneity
[J]. China Oncology, 2020, 30(5): 394-400.
|
[3] |
SHI Zhiqiang , QIU Pengfei , LIU Yanbing , ZHAO Tong , SUN Xiao , CHEN Peng , WANG Chunjian , ZHANG Zhaopeng , CONG Binbin , WANG Yongsheng .
Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer
[J]. China Oncology, 2020, 30(3): 186-191.
|
[4] |
ZHENG Xiaocui, WANG Xipeng.
Progress of single-cell sequencing in solid tumors
[J]. China Oncology, 2019, 29(7): 535-539.
|
[5] |
ZHENG Weizhen, SUN Jujie, LIU Yanbing, QIU Pengfei, BI Zhao, ZHAO Tong, WANG Yongsheng.
Validation and modification study of axillary node pathologic complete response predictive model after neoadjuvant chemotherapy for breast cancer
[J]. China Oncology, 2019, 29(6): 445-451.
|
[6] |
BI Zhao, LIU Jingjing, CHEN Peng, LIU Yanbing, ZHAO Tong, SUN Xiao, QIU Pengfei, WANG Yongsheng.
Internal mammary sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy
[J]. China Oncology, 2019, 29(2): 131-135.
|
[7] |
CAO Xiaoshan, CONG Binbin.
The progress of treatment for triple-negative breast cancer in the era of precision medicine
[J]. China Oncology, 2019, 29(12): 971-976.
|
[8] |
ZHENG Xiaying, CHEN Junxia.
Expression of circRNA hsa_circ_0005320 in triple-negative breast cancer and its effect on cell proliferation
[J]. China Oncology, 2019, 29(11): 845-854.
|
[9] |
ZHU Xiuzhi, CHEN Li, JI Lei, GAO Yu, WANG Zhonghua.
Advances in the treatment of triple-negative breast cancer with CDK4/6 inhibitors
[J]. China Oncology, 2019, 29(11): 899-905.
|
[10] |
YANG Rui, CHEN Junxia.
Effects of circular RNA hsa_circ_0058514 on the development and progression of triple-negative breast cancer
[J]. China Oncology, 2019, 29(1): 9-18.
|
[11] |
SUN Jiajun, LU Renquan, ZHENG Hui, et al.
The value of serum HER2-ECD level in neoadjuvant chemotherapy for breast cancer
[J]. China Oncology, 2019, 29(1): 32-36.
|
[12] |
LI Jiawei, SHI Zhaoting, HOU Yingmin, et al.
Clinicopathological and immunohistochemical basis for sonographic characteristics of triple-negative invasive breast cancer
[J]. China Oncology, 2019, 29(1): 37-44.
|
[13] |
SHI Zhiqiang, QIU Pengfei, CONG Binbin, et al.
Progress in selective elimination of breast surgery after neoadjuvant chemotherapy for breast cancer
[J]. China Oncology, 2018, 28(8): 609-613.
|
[14] |
SHEN Haoyuan, HU Chaohua, HAN Yuntao, et al.
The exploration of clinical pathological characteristics and the diagnosis and treatment strategy of 56 patients with occult breast cancer
[J]. China Oncology, 2018, 28(6): 429-434.
|
[15] |
SHI Zhiqiang, QIU Pengfei, CONG Binbin, et al.
Neoadjuvant chemotherapy and axillary de-escalation management for patients with clinically node-negative breast cancer
[J]. China Oncology, 2018, 28(12): 922-927.
|